Nasonex is a nasal spray used to treat allergies. In clinical trials, 1671 subjects were given a placebo, and 2 of them developed upper respiratory tract infections. Another 2103 patients were treated with Nasonex and 6 of them developed upper respiratory tract infections. Assume that Nasonex has no effect on upper respiratory tract infections, so that the rate of those infections also applies to Nasonex users. Using the placebo rate of 2/1671, simulate groups of 2103 subjects given the Nasonex treatment, and determine whether a result of 6 upper respiratory tract infections could easily occur. What does that suggest about Nasonex as a cause of upper respiratory tract infections?